| Oct 22 |
Nexalin Technology Announces Planned Clinical Trial Utilizing Gen-3 Halo Headset in Partnership with UC San Diego & San Diego VA
|
| Oct 18 |
Mixed results for Nexalin’s transcranial alternating current stimulation trial
|
| Oct 17 |
New Study Shows Nexalin’s Deep Intracranial Frequency Stimulation (DIFS) Significantly Improves Memory and Cognitive Function in Alzheimer’s Patients
|
| Oct 17 |
EXCLUSIVE: Nano-Cap Nexalin's Drug-Free Alternative For Alzheimer's Shows Improved Memory, Cognitive Function In Small Study
|
| Oct 14 |
Nexalin Technology Appoints Carolyn Shelton as Senior Vice President of Clinical, Quality & Regulatory Affairs
|
| Sep 5 |
Nexalin Technology Participates in Congressional Roundtable Focused on Emerging Virtual Therapeutic Options for Opioid Treatment
|
| Aug 11 |
Nexalin Technology Second Quarter 2024 Earnings: US$0.17 loss per share (vs US$0.11 loss in 2Q 2023)
|
| Jul 26 |
Nexalin Interview to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
|
| Jul 18 |
Nexalin Technology Selected to Join Industry Coalition: Breaking Barriers to Substance Use Recovery
|
| Jul 1 |
Nexalin Technology Announces Closing of $5.2 Million Public Offering
|
